Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma

Clinical Biochemistry

Volumn 43, Issue 12, 2010, Pages 1003-1008

  Zhang, Qianyun ^a,b   Xiao, Qin ^b   Lin, Zhen ^b   Ying, Xitang ^c   Li, Zhenjia ^c   Lin, Jin Ming ^b  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c Beijing Chemclin Biotech Co Ltd   (China)

Author keywords

AFP; Combined AFP CA19 9; Glypican 3; Hepatocellular carcinoma (HCC)

Indexed keywords

GLYPICAN 3; IODINE 125; TUMOR MARKER; GLYPICAN;

ARTICLE; CANCER DIAGNOSIS; CHEMOLUMINESCENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; LIVER CELL CARCINOMA; LIVER DISEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; ADULT; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMAN; LIMIT OF DETECTION; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROCEDURES;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GLYPICANS; HUMANS; LIMIT OF DETECTION; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOIMMUNOASSAY;

EID: 77954310523     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.04.074     Document Type: Article

References (33)

1. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
2. Dufour D.R., Lott J.A., Nolte F.S., Gretch D.R., Koff R.S., Seeff L.B. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000, 46:2050-2068.
3. Koteish A., Thuluvath P.J. Screening for hepatocellular carcinoma. J Vasc Interv Radiol 2002, 13:185-190.
4. Ryder S.D. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003, 52:1-8.
5. Lamerz R, Hayes P, Hoffmann RT, Löhe F, Shiratori Y, Taketa K. National Academy of clinical biochemistry guidelines for the use of tumor markers in primary liver cancer 2003, http://www.nacb.org/lmpg/tumor/chp3d_liver.pdf.
6. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328:1797-1801.
7. Cheng H.T., Chang Y.H., Chen Y.Y., Lee T.H., Tai D.I., Lin D.Y. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. J Chin Med Assoc 2007, 70:310-317.
8. Nakagawa T., Miyoshi E., Yakushijin T., Hiramatsu N., Igura T., Hayashi N., et al. Glycomic analysis of alpha-fetoprotein L3 in hepatoma cell lines and hepatocellular carcinoma patients. J Proteome Res 2008, 7:2222-2233.
9. Wang C.S., Lin C.L., Lee H.C., Chen K.Y., Chiang M.F., Chen H.S., et al. Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005, 11:6115-6119.
10. Tommaso L.D., Destro A., Seok J.Y., Balladore E., Terracciano L., Sangiovanni A., et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009, 50:746-754.
11. Sauerland C., Engelking C., Wickham R., Pearlstone D.B. Cancers of the pancreas and hepatobiliary system. Semin Oncol Nurs 2009, 25:76-92.
12. Pissaia A., Bernard J.D., Scatton O., Soubrane O., Conti F., Calmus Y. Significance of serum tumor markers carcinoembryonic antigen, CA19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation. Transplant Proc 2009, 41:682-684.
13. Khalifa A., Mady E.A., Abadeer N., Kamal A. Differential tumor markers and hepatitis markers profile in liver tumors. Anticancer Res 1999, 19:2495-2500.
14. Usui Y., Miura H., Kimura Y., Takayama S., Nakayama M. Hepatocellular carcinoma producing carcinoembryonic antigen and carbohydrate antigen 19-9. Intern Med 1992, 31:791-793.
15. Filmus J., Selleck S.B. Glypicans: proteoglycans with a surprise. J Clin Invest 2001, 108:497-501.
16. Tetsuya N., Toshiro K., Shosuke I., Kazumasa W., Mikio M., Yoshiaki I., et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004, 10:6612-6621.
17. Wang B, Wab M. Methods for diagnosing and treating prostate cancer, US Patent 20070154964.
18. Sung Y.K., Hwang S.Y., Park M.K., Farooq M., Han I.S., Bae H.I., et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003, 94:259-262.
19. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
20. Tetsuya N., Yoshihiro Y., Satoru S., Mikio M., Hiroyuki K., Yutaka M., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306:16-25.
21. Zhu Z.W., Friess H., Wang L., Abou-Shady M., Zimmermann A., Lander A.D., et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001, 48:558-564.
22. Yamauchi N., Watanabe A., Hishinuma M., Ohashi K.I., Midorikawa Y., Morishita Y., et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005, 18:1591-1598.
23. Murthy S.S., Shen T., De Rienzo A., Lee W.C., Ferriola P.C., Jhanwar S.C., et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000, 19:410-416.
24. Xiang Y.Y., Ladeda V., Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001, 20:7408-7412.
25. Kim H., Xu G.L., Borczuk A.C., Busch S., Filmus J., Capurro M., et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 2003, 29:694-701.
26. Zhu Z., Friess H., Kleeff J., Wang L., Wirtz M., Zimmermann A., et al. Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. Am J Surg 2002, 184:78-83.
27. Lin H., Huber R., Schlessinger D., Morin P.J. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999, 59:807-810.
28. Pilia G., Hughes-Benzie R.M., MacKenzie A., Baybayan P., Chen E.Y., Huber R., et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nature Genetics 1996, 12:241-247.
29. 2-terminal fragment of glypican-3 as a serum marker for early-stage of hepatocellular carcinoma. Cancer Res 2004, 64:2418-2423.
30. Capurro M., Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 2005, 65:372-373.
31. Emoto K., Yamashita S., Okada Y. Mechanisms of heat-induced antigen retrieval: does pH or ionic strength of the solution play a role for refolding antigens. J Histochem Cytochem 2005, 53:1311-1321.
32. Hara T., Nakamura K., Satomura S., Matsuura S. Noncompetitive immunoassay of thyroxine using a liquid-phase binding assay. Anal Chem 1994, 66:351-354.
33. Tommaso L.D., Franchi G., Park Y.N., Fiamengo B., Destro A., Morenghi E., et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45:725-734.